by Admin | Nov 7, 2024
Introduction Modified nucleoside triphosphates (NTPs) are the master keys that unlock the therapeutic potential of mRNA. By strategically incorporating these chemically modified building blocks during mRNA synthesis, researchers can enhance stability, translation...
by Admin | Oct 22, 2024
Introduction The development of mRNA vaccines to fight COVID-19 marked a transformative leap in medicine, showcasing the power of RNA technology to tackle infectious diseases. Despite its groundbreaking success, mRNA has some limitations—such as instability, the need...
by Admin | Oct 14, 2024
mRNA therapeutics have emerged as a revolutionary force in medicine, riding the wave of success initially generated by mRNA vaccines for COVID-19. However, as the field progresses from vaccines to protein replacement therapies and beyond, it faces distinct hurdles,...
by Admin | Sep 18, 2024
Collaboration expands Areterna’s reach in Europe and strengthens Biomay’s mRNA CDMO offerings. Gaithersburg, MD and Vienna, Austria (September 18, 2024) — Areterna LLC, a company with a mission to democratize mRNA products by supplying low-cost GMP raw materials,...
by Admin | Jul 23, 2024
Synthgene Biotechnology, Areterna’s parent company, has been a leading producer of GMP-grade cap analogs, NTPs, and modified NTPs for several years, establishing a strong reputation for quality and reliability in the industry. Our raw materials play a crucial...
